Genomics Sample Articles & Analysis
14 news found
The GARNER Study is the largest HR-NMIBC real-world patient cohort ever assembled with both clinical and genomic detail and the first study of the broader GARNER Bladder Cancer Program. ...
CytoRecovery, Inc., a leader in the marker free enrichment, sorting, and recovery of live cells, presented recent study results at the American Association for Cancer Research (AACR) Annual Meeting 2022 currently being held in New Orleans. The study was completed in collaboration with The Laboratory of Integrative Cancer Immunology, National Cancer Institute (NCI/NIH Bethesda, MD) and Virginia ...
GRIDSS/PURPLE/LINX Workflow, used for somatic genomic rearrangement detection and classification on WGS data. This workflow takes a pair of matched tumor/normal BAM files and produces allele-specific copy number of every base of the genome, overall sample purity and ploidy, annotated SV clusters and gene fusion predictions. Moreover, it outputs ...
Patent 10,894,990, was awarded January 19, 2021, for a “High Throughput Method For Identification and Sequencing of Unknown Microbial and Eukaryotic Genomes from Complex Mixtures.” The patent protects the bacterial identification method, utilizing the novel 16S-ITS-23S amplicon, found in Intus Biosciences flagship StrainID kits. ...
Collection of fresh-frozen tumor samples is often challenging or infeasible, leading many studies to rely on formalin-fixed, paraffin-embedded (FFPE) tumor tissue samples. Because these tissues are often paired with a great deal of clinical and outcome data, analysis of these archives has the potential to lead to major advances in cancer treatment and prevention. ...
He noted that sample quality has a direct impact on the fidelity of sequencing data. ...
Most significantly, the cells harboring genomic anomalies can have a proliferative advantage and overtake the culture, compromising the validity of study data and resulting in the loss of samples, time and funds. ...
As an additional check, they consulted methylation data from normal tissues and seven different types of cancerous tumors in The Cancer Genome Atlas , a database funded by the National Cancer Institute and the National Human Genome Research Institute. ...
For more information about Agilent SureFISH probes, visit www.agilent.com/genomics/SureFISH. About Agilent in Genomics Agilent is a global leader in target enrichment for next-generation sequencing and genomic microarrays. The Agilent SureSelect and HaloPlex target enrichment systems enable researchers to easily choose which segments of a ...
The company's human genome CGH microarrays are available in multiple formats with bundling options available. ...
For more information, click here to visit Agilent's SureSelect Human All Exon Kits website. About Agilent in Genomics Agilent Technologies Inc. is a global leader in target enrichment for next-generation sequencing and genomic microarrays. The Agilent SureSelect and HaloPlex target enrichment systems enable researchers to easily choose which segments of a ...
Agilent Technologies Inc., (NYSE: A) today introduced SurePrint G3 CGH+SNP cancer catalog microarrays, addressing the growing need of researchers to detect both copy number and copy-neutral aberrations in cancer tissue samples in the same experiment. The new microarray release is accompanied by the release of Agilent CytoGenomics 2.0 software, which now includes support for ...
"We tested it on our ENU-mutagenized mouse genome, in which one ENU-induced mutation was induced approximately every 1Mb. ...
We never really knew for sure. The complete genome introduced today holds the answers to many of these questions. ...